The Mexico Fund, Inc. Pays Distribution WASHINGTON,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
The Mexico Fund, Inc. Pays Distribution

WASHINGTON, DC--(Marketwired - Apr 21, 2015) - The Mexico Fund, Inc. ( NYSE : MXF ) announced that it will pay today a distribution of $0.5660 per share in cash to stockholders of record as of April 9, 2015. According to the terms of the Fund's Managed Distribution Plan (MDP), this distribution is the equivalent of 2.5% of the Fund's net asset value per share (NAV) as of December 31, 2014.

As a general matter, the amount of distributable income for each fiscal period depends on the aggregate gains and losses realized by the Fund during the entire year. Distributions may consist of net investment income, capital gains and return of capital, but the character of these distributions cannot be determined until after the end of the Fund's fiscal year. 

However, under the Investment Company Act of 1940, the Fund is required to indicate the source of each distribution to stockholders. The following table sets forth an estimate of the sources of the April 21, 2015 distribution and distributions paid in the current fiscal year:

         
Distribution Estimates   April 2015   Fiscal Year-to-date (YTD) 1
Source   Per Share Amount   Percent of Current Distribution   Per Share Amount   Percent of Fiscal Year Distributions
Net Investment Income   -   -   $0.0419   3.23%
Net Realized Short-Term Capital Gains   -   -   $0.1508   11.61%
Net Realized Long-Term Capital Gains   $0.5660   100.00%   $1.1059   85.16%
Return of Capital (or other Capital Source)   -   -   -   -
Total Distribution   $0.5660   100.00%   $1.2986   100.00%
                 

Information regarding the Fund's performance and distribution rates is set forth below:

   
Average Annual Total Return for the 5-year period ended on March 31, 2015 2 6.46%
Current Annualized Distribution Rate (current fiscal year) 3 7.92%
Current Fiscal Year Cumulative Total Return 4 (13.48)%
Cumulative Distribution Rate (current fiscal year) 5 3.28%
   

1 The Fund's current fiscal year began on November 1, 2014.

2 Average Annual Total Return represents the simple arithmetic average of the Annual NAV Total Returns of the Fund for the last five years. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

3 The Current Annualized Distribution Rate is the Cumulative Distribution Rate as of March 31, 2015, annualized as a percentage of the Fund's NAV at the same date.

4 Current Fiscal Year Cumulative Total Return is the percentage change in the Fund's NAV from November 1, 2014 through March 31, 2015, including distributions paid and assuming reinvestment of those distributions.

5 Cumulative Distribution Rate for the Fund's current fiscal period (November 1, 2014 through March 31, 2015) measured on the dollar value of distributions in the period as a percentage of the Fund's NAV as of March 31, 2015.

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's MDP.

The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report the distribution for federal income tax purposes.

For further information, contact the Fund's Investor Relations office at 011-52-55-5282-8900, or by email at investor-relations@themexicofund.com . 

www.themexicofund.com

The Mexico Fund, Inc. is a non-diversified closed-end management investment company with the investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The Fund provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

This press release may contain certain forward-looking statements regarding future circumstances. These forward-looking statements are based upon the Fund's current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements including, in particular, the risks and uncertainties described in the Fund's filings with the Securities and Exchange Commission. Actual results, events, and performance may differ. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Fund undertakes no obligation to release publicly any revisions to these forward looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The inclusion of any statement in this release does not constitute an admission by The Mexico Fund or any other person that the events or circumstances described in such statement are material.

CONTACT : Alberto Gomez Pimienta The Mexico Fund, Inc. 011-52-55-5282-8900 CONTACT : Patricia Baronowski Pristine Advisers, LLC (631) 756-2486

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 79

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 72

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 140

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 93

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 312

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 87

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading

Top 5 Most Recently Viewed Articles

Nippon Express Europe Partners with Formag for Logistics Support

Updated Category News Views 213

Nippon Express Europe and Formag Form New Logistics Partnership Nippon Express Europe GmbH, part of NIPPON EXPRESS HOLDINGS, INC., has recently signed a cooperation agreement with Ukrainian logistics provider, Formag-Kiev. This significant collaboration aims to provide essential logistical support for the reconstruction of Ukraine. Commitment to Ukrainian Reconstruction...

Continue Reading
Escalating Legal Action Over LIBRA Token Sparks Controversy

Updated Category News Views 265

Legal Developments in the LIBRA Token Case A prominent Argentine lawyer has made headlines by calling for global law enforcement to apprehend a cryptocurrency figure involved in the LIBRA token controversy. Details of the Extradition Request Gregorio Dalbon, known for his defense work with former Argentine President Cristina Fernandez in a prominent corruption matter, has...

Continue Reading
Tesla Prevails in Motion to Dismiss Racial Bias Lawsuit

Updated Category News Views 230

Tesla's Legal Victory Against Racial Bias Allegations Under the direction of Elon Musk, Tesla Inc. (NASDAQ: TSLA) has successfully overturned a significant class action lawsuit that was brought forth by more than 6,000 African American workers. These workers alleged racial discrimination at Tesla's Fremont assembly plant. This ruling is a key moment in the ongoing...

Continue Reading
ZenaTech Unveils Specialized AI Hub to Bolster US Defense Tactics

Updated Category News Views 100

ZenaTech Launches Innovative AI Development Center Vancouver, British Columbia – ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) has taken a significant stride toward advancing artificial intelligence technologies by establishing Zena AI, Inc. This new AI Development Center will focus on crafting specialized AI solutions tailored for defense and homeland security...

Continue Reading
Investors Reminded of Action Timeline Against ICON plc - ICLR

Updated Category News Views 172

Understanding the Legal Proceedings Against ICON plc In an important reminder for shareholders, Kahn Swick & Foti, LLC is emphasizing the critical timeline for investors affected by losses from their holdings in ICON plc (NASDAQ: ICLR). The firm, led by former Louisiana Attorney General Charles C. Foti, Jr., is urging investors who incurred losses exceeding $100,000 to...

Continue Reading